COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Hydroxychloroquine and Kaletra treatment according to the national guideline for the treatment of COVID-19 and Atorvastatin, 1 tablet, 20 mg, daily, during hospital
Sponsors
Bojnourd University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: COVID-19 infected people who are inpatient in the hospital
Exclusion criteria
Exclusion criteria: type 1 diabetes ketoacidosis Uncompensated heart failure sever renal failure GFR<30ml/min metabolic acidosis structural respiratory dysfunction Indications for Intubation at the registering time to the hospital
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization. Timepoint: end of study. Method of measurement: Patient file in the hospital. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality rate. Timepoint: end of study. Method of measurement: Patient file in the hospital.;Intubation indication. Timepoint: end of study. Method of measurement: Patient file in the hospital.;Duration of intubation. Timepoint: end of study. Method of measurement: Patient file in the hospital.;Duration of sign and symptoms (fever, cough ,...). Timepoint: daily. Method of measurement: Patient file in the hospital and questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Ghafoori
Bojnourd University of Medical Sciences
Outcome results
None listed